Optimizing Management of KRAS-Mutated Malignancies: Practical Approaches to Dosing, Monitoring, and Adverse Event Management

Activity Overview

The GOG Foundation, Inc. and GOG Partners welcomes gynecologic oncologists, oncologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with gynecologic malignancies to join us in-person for the Optimizing Management of KRAS-Mutated Malignancies: Practical Approaches to Dosing, Monitoring, and Adverse Event Management, an Educational Symposium that was presented at the 2026 SGO Allied Health Professionals Meeting in Chicago, Illinois on Saturday, October 17, 2026.

This ACCME accredited educational program is designed to provide nurse practitioners, PAs, Allied Health Professionals and clinicians with a comprehensive, evidence-based overview of managing patients with KRAS-mutated malignancies. Through case-based learning, participants will explore practical strategies for adverse event prevention, recognition and management, including dermatologic toxicities, ocular disorders, and fluid retention. 

The program will also highlight key considerations in dosing, monitoring for safety and efficacy, and the interpretation of biomarker testing, including KRAS mutation identification and patient selection. Special attention will be given to management approaches associated with targeted pathway inhibition (e.g., MAPK pathway inhibitors such as MEK and RAF pathway-directed therapies), with a focus on translating clinical trial data into real-world practice.  Designed to support informed, patient-centered care, this activity emphasizes practical application, multidisciplinary coordination, and balanced review of current therapeutic approaches. 

Learning Objectives

At the conclusion of this activity, participants should be able to: 

1. Recognize and understand prevention and management options of common adverse events associated with targeted therapies, including rash, edema, and visual disturbances, using evidence-based approaches. 
2. Apply biomarker-driven strategies to identify appropriate patients for targeted therapies, including understanding KRAS mutations and available testing methodologies. 
3. Implement effective dosing strategies that optimize treatment adherence while minimizing toxicity. 
4. Develop monitoring plans to assess treatment safety and efficacy in patients receiving targeted therapies. 
5. Translate clinical evidence into practice through case-based application of adverse event management and therapeutic decision-making. 

Disclosure Declaration

In accordance with the ACCME Accreditation Criteria, The GOG Foundation, Inc., as the accredited provider of this activity, must ensure that anyone in a position to control the content of the educational activity has disclosed all relevant financial relationships with any ineligible company *(formally known as commercial interests). All Committee/Planning/Faculty members were required to disclose all financial relationships and speakers were required to disclose any financial relationship as it pertains to the content of the presentations.The ACCME does not consider providers of clinical service directly to patients to be an ineligible company. “Relevant” financial relationships are financial transactions (in any amount) occurring within the past 24 months that may create a conflict of interest.

Please note we have advised the speakers that it is their responsibility to disclose at the start of their presentation if they will be describing the use of a device, product, or drug that is not FDA approved or the off-label use of an approved device, product, or drug or unapproved usage.  The requirement for disclosure is not intended to imply any impropriety of such relationships, but simply to identify such relationships through full disclosure, and to allow the audience to form its own judgments regarding the presentation.

All of the relevant financial relationships listed for these individuals have been mitigated. However, if you perceive a bias during a session, please report the circumstances on the session evaluation form.

NEW TERM *An “ineligible company” is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.